Interleukin-17 in inflammatory myopathies

Current Rheumatology Reports

Volumn 14, Issue 3, 2012, Pages 252-256

  Tournadre, Anne ^a,b   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Dermatomyositis; IL 17; IL 23; Inflammatory myopathies; Interleukin 17; Myositis; Polymyositis; Th17; TLR; Toll like receptor

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 17F; INTERLEUKIN 23; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 6; SECONDARY LYMPHOID TISSUE CHEMOKINE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB;

ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; CELL DIFFERENTIATION; CELL FUNCTION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DERMATOMYOSITIS; HELPER CELL; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; INCLUSION BODY MYOSITIS; INNATE IMMUNITY; MONOCYTE; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE CELL; MUSCLE TISSUE; MUSCLE WEAKNESS; MYOSITIS; POLYMYOSITIS; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-17; MOLECULAR TARGETED THERAPY; MUSCLE CELLS; MYOSITIS; TH17 CELLS;

EID: 84860780328     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-012-0242-x     Document Type: Article

References (19)

1. • Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med. 2009;361:888-98. This review describes the origin and functions of IL-17 and Th17 cells.
2. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide comparison between IL-17A- and IL- 17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009;182:3112-20.
3. Zrioual S, Toh ML, Tournadre A, Zhou Y, Cazalis MA, Pachot A, Miossec V. Miossec P IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR + CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J Immunol. 2008;180:655-63.
4. Tournadre A, Miossec P. Cytokine response in inflammatory myopathies. Curr Rheumatol Rep. 2007;9:286-90. (Pubitemid 47262608)
5. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003;137:125-33. (Pubitemid 36351574)
6. Chevrel G, Granet C, Miossec P. Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NFkappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors. Ann Rheum Dis. 2005;64:1257-62. (Pubitemid 41206239)
7. Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, Chang J, Dwivedi S, Mitsak M, Chen YW, Plotz P, Rosen A, Hoffman E, Raben N. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005;52:1824-35. (Pubitemid 40852891)
8. Li YP, Reid MB. Effect of tumor necrosis factor-alpha on skeletal muscle metabolism. Curr Opin Rheumatol. 2001;13:483-7. (Pubitemid 33070964)
9. Austin L, Bower J, Kurek J, Vakakis N. Effects of leukaemia inhibitory factor and other cytokines on murine and human myoblast proliferation. J Neurol Sci. 1992;112:185-91.
10. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Rönnblom L, Alm GV, Lundberg IE. A possiblemechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti- Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56:3112-24. (Pubitemid 47502759)
11. •• Tournadre A, Lenief V, Miossec P. Expression of TLR3 and TLR7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 2010;62:2144-51. This study reports the synergistic effect of IL-17 with TLR3 activation on the IL-6 and CCL20 production by muscle cells and the differential contribution of Th1 and Th17 cytokines in the regulation of TLR3 expression.
12. •• Tournadre A, Lenief V, Eljaafari-Dany A, Miossec P. Immature muscle precursors are a source of IFNβ in myositis: role of TLR3 activation and contribution to HLA class I up-regulation. Arthritis Rheum 2011; Sep 14. doi:10.1002/art.33350. [Epub ahead of print]. This study reports the role of TLR3 activation and immature muscle precursors in myositis pathogenesis. The detection of activated DCs expressing CLRs and associated with expression of IL-12 and IL-23 cytokines involved in Th1 and Th17 polarization is identified.
13. Toh ML, Kawashima M, Zrioual S, Hot A, Miossec P, Miossec P. IL17 inhibits human Th1 differentiation through IL12R beta 2 downregulation. Cytokine. 2009;48:226-30.
14. Page G, Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum. 2004;50:199-208. (Pubitemid 38084305)
15. • Tournadre A, Porcherot M, Chérin P, Marie I, Hachulla E, Miossec P. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine. 2009;46:297-301. This study reports the presence of IL-17-producing cells in myositis muscle but a main Th1 profile. The detection of immature and mature DCs is identified in muscle biopsies from PM and DM patients.
16. Kondo M, Murakawa Y, Harashima N, Kobayashi S, Yamaguchi S, Harada M. Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology. 2009;128:589-99.
17. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Durez P, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52ra72.
18. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 2001;44:1293-303. (Pubitemid 32537527)
19. Ohyanagi N, Ishido M, Suzuki F, Kaneko K, Kubota T, Miyasaka N, Nanki T. Retinoid ameliorates experimental autoimmune myositis, with modulation of Th cell differentiation and antibody production in vivo. Arthritis Rheum. 2009;60:3118-27.